ID: ALA5179766

Max Phase: Preclinical

Molecular Formula: C19H17NO4S

Molecular Weight: 355.42

Associated Items:

Representations

Canonical SMILES:  COc1cc(/C=C2\SC(=O)NC2=O)ccc1OCc1ccc(C)cc1

Standard InChI:  InChI=1S/C19H17NO4S/c1-12-3-5-13(6-4-12)11-24-15-8-7-14(9-16(15)23-2)10-17-18(21)20-19(22)25-17/h3-10H,11H2,1-2H3,(H,20,21,22)/b17-10-

Standard InChI Key:  IPQOKWNEKIARGZ-YVLHZVERSA-N

Associated Targets(non-human)

3T3-L1 3664 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 355.42Molecular Weight (Monoisotopic): 355.0878AlogP: 3.91#Rotatable Bonds: 5
Polar Surface Area: 64.63Molecular Species: ACIDHBA: 5HBD: 1
#RO5 Violations: 0HBA (Lipinski): 5HBD (Lipinski): 1#RO5 Violations (Lipinski): 0
CX Acidic pKa: 6.20CX Basic pKa: CX LogP: 3.77CX LogD: 2.62
Aromatic Rings: 2Heavy Atoms: 25QED Weighted: 0.82Np Likeness Score: -0.96

References

1. Madrigal-Angulo JL, Ménez-Guerrero C, Estrada-Soto S, Ramírez-Espinosa JJ, Almanza-Pérez JC, León-Rivera I, Hernández-Núñez E, Aguirre-Vidal Y, Flores-León CD, Aguayo-Ortíz R, Navarrete-Vazquez G..  (2022)  Synthesis, in vitro, in silico and in vivo hypoglycemic and lipid-lowering effects of 4-benzyloxy-5-benzylidene-1,3-thiazolidine-2,4-diones mediated by dual PPAR α/γ modulation.,  70  [PMID:35598791] [10.1016/j.bmcl.2022.128804]

Source